STOCK TITAN

[S-8 POS] Amedisys Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Amedisys, Inc. submitted a notice to deregister shares of its common stock that remain registered but unsold or otherwise unissued under a series of previously filed S-8 registration statements. The filing lists eight prior S-8 registrations covering employee stock purchase and various stock option and omnibus incentive plans, with registered amounts ranging from 75,000 to 4,100,000 shares per filing. The company states that the listed share numbers do not reflect interim corporate actions such as stock splits and identifies Richard Ashworth as President and CEO signing the notice.

Amedisys, Inc. ha presentato una comunicazione per cancellare dalla registrazione le azioni del suo capitale ordinario che risultano ancora registrate ma non vendute o non emesse ai sensi di una serie di precedenti dichiarazioni di registrazione S-8. Il deposito elenca otto registrazioni S-8 precedenti relative a piani di acquisto azionario per i dipendenti e a vari piani di opzioni azionarie e di incentivi omnibus, con quantità registrate che vanno da 75.000 a 4.100.000 azioni per ciascun deposito. La società precisa che i numeri delle azioni indicati non riflettono operazioni societarie intermedie, come frazionamenti azionari, e indica Richard Ashworth come Presidente e CEO che firma la comunicazione.

Amedisys, Inc. presentó un aviso para dejar de registrar acciones de su capital social que permanecen registradas pero no vendidas o no emitidas bajo una serie de declaraciones de registro S-8 presentadas anteriormente. La presentación enumera ocho registros S-8 previos que cubren planes de compra de acciones para empleados y varios planes de opciones e incentivos omnibus, con cantidades registradas que varían de 75.000 a 4.100.000 acciones por presentación. La compañía declara que los números de acciones listados no reflejan operaciones corporativas interinas, como desdoblamientos de acciones, e identifica a Richard Ashworth como Presidente y CEO que firma el aviso.

Amedisys, Inc.는 이전에 제출된 일련의 S-8 등록명세서에 따라 여전히 등록되어 있으나 미판매 또는 미발행 상태인 보통주를 등록말소(deregister)하기 위한 통지를 제출했습니다. 제출서류에는 직원 주식 매입 계획과 다양한 주식옵션 및 총괄 인센티브 계획을 포함하는 8건의 이전 S-8 등록이 기재되어 있으며, 각 등록 건당 등록 주식 수는 75,000주에서 4,100,000주까지 다양합니다. 회사는 기재된 주식 수가 주식 분할과 같은 중간 기업행위를 반영하지 않는다고 명시하고, 해당 통지에 서명한 자로 리차드 애쉬워스(Richard Ashworth)를 사장 겸 CEO로 지목했습니다.

Amedisys, Inc. a soumis un avis visant à radier de l’enregistrement des actions ordinaires qui restent enregistrées mais non vendues ou non émises au titre d’une série de déclarations d’enregistrement S-8 précédemment déposées. Le dossier répertorie huit enregistrements S-8 antérieurs couvrant des plans d’achat d’actions pour les employés ainsi que divers plans d’options et d’incitation omnibus, avec des quantités enregistrées allant de 75 000 à 4 100 000 actions par dépôt. La société précise que les nombres d’actions indiqués ne tiennent pas compte d’opérations corporatives intermédiaires telles que des divisions d’actions, et identifie Richard Ashworth comme président et CEO signataire de l’avis.

Amedisys, Inc. hat eine Mitteilung eingereicht, die darauf abzielt, Aktien seines Stammkapitals, die weiterhin registriert, aber nicht verkauft oder anderweitig nicht ausgegeben wurden, aus der Registrierung zu nehmen. Die Einreichung listet acht frühere S-8-Registrierungen auf, die Mitarbeiteraktienkaufpläne sowie verschiedene Options- und Omnibus-Anreizpläne abdecken, mit registrierten Stückzahlen von 75.000 bis 4.100.000 Aktien pro Einreichung. Das Unternehmen erklärt, dass die aufgeführten Aktienzahlen Zwischenaktionen wie Aktiensplits nicht berücksichtigen, und nennt Richard Ashworth als Präsidenten und CEO, der die Mitteilung unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Routine deregistration of unsold or unissued plan shares; no operational or financial detail disclosed.

The filing is a procedural notice to remove from registration shares previously reserved under employee equity plans that remain unsold or unissued. This typically reflects housekeeping of the company’s registered securities and does not, by itself, change outstanding shares or imply plan cancellations. The document lists the original registration identifiers and nominal share amounts for transparency but clarifies that interim corporate actions may alter those counts.

TL;DR Deregistration is administrative and non-material absent additional disclosures on stock activity or plan changes.

The notice specifies eight S-8 registrations (including filings from 1998 through 2018) and the original registered share quantities for various employee plans and purchase programs. There are no financial statements, issuance data, or indications of material corporate actions in this filing. Investors seeking impact on dilution or outstanding share count must reference separate disclosures that report actual issuances and corporate actions.

Amedisys, Inc. ha presentato una comunicazione per cancellare dalla registrazione le azioni del suo capitale ordinario che risultano ancora registrate ma non vendute o non emesse ai sensi di una serie di precedenti dichiarazioni di registrazione S-8. Il deposito elenca otto registrazioni S-8 precedenti relative a piani di acquisto azionario per i dipendenti e a vari piani di opzioni azionarie e di incentivi omnibus, con quantità registrate che vanno da 75.000 a 4.100.000 azioni per ciascun deposito. La società precisa che i numeri delle azioni indicati non riflettono operazioni societarie intermedie, come frazionamenti azionari, e indica Richard Ashworth come Presidente e CEO che firma la comunicazione.

Amedisys, Inc. presentó un aviso para dejar de registrar acciones de su capital social que permanecen registradas pero no vendidas o no emitidas bajo una serie de declaraciones de registro S-8 presentadas anteriormente. La presentación enumera ocho registros S-8 previos que cubren planes de compra de acciones para empleados y varios planes de opciones e incentivos omnibus, con cantidades registradas que varían de 75.000 a 4.100.000 acciones por presentación. La compañía declara que los números de acciones listados no reflejan operaciones corporativas interinas, como desdoblamientos de acciones, e identifica a Richard Ashworth como Presidente y CEO que firma el aviso.

Amedisys, Inc.는 이전에 제출된 일련의 S-8 등록명세서에 따라 여전히 등록되어 있으나 미판매 또는 미발행 상태인 보통주를 등록말소(deregister)하기 위한 통지를 제출했습니다. 제출서류에는 직원 주식 매입 계획과 다양한 주식옵션 및 총괄 인센티브 계획을 포함하는 8건의 이전 S-8 등록이 기재되어 있으며, 각 등록 건당 등록 주식 수는 75,000주에서 4,100,000주까지 다양합니다. 회사는 기재된 주식 수가 주식 분할과 같은 중간 기업행위를 반영하지 않는다고 명시하고, 해당 통지에 서명한 자로 리차드 애쉬워스(Richard Ashworth)를 사장 겸 CEO로 지목했습니다.

Amedisys, Inc. a soumis un avis visant à radier de l’enregistrement des actions ordinaires qui restent enregistrées mais non vendues ou non émises au titre d’une série de déclarations d’enregistrement S-8 précédemment déposées. Le dossier répertorie huit enregistrements S-8 antérieurs couvrant des plans d’achat d’actions pour les employés ainsi que divers plans d’options et d’incitation omnibus, avec des quantités enregistrées allant de 75 000 à 4 100 000 actions par dépôt. La société précise que les nombres d’actions indiqués ne tiennent pas compte d’opérations corporatives intermédiaires telles que des divisions d’actions, et identifie Richard Ashworth comme président et CEO signataire de l’avis.

Amedisys, Inc. hat eine Mitteilung eingereicht, die darauf abzielt, Aktien seines Stammkapitals, die weiterhin registriert, aber nicht verkauft oder anderweitig nicht ausgegeben wurden, aus der Registrierung zu nehmen. Die Einreichung listet acht frühere S-8-Registrierungen auf, die Mitarbeiteraktienkaufpläne sowie verschiedene Options- und Omnibus-Anreizpläne abdecken, mit registrierten Stückzahlen von 75.000 bis 4.100.000 Aktien pro Einreichung. Das Unternehmen erklärt, dass die aufgeführten Aktienzahlen Zwischenaktionen wie Aktiensplits nicht berücksichtigen, und nennt Richard Ashworth als Präsidenten und CEO, der die Mitteilung unterzeichnet.

As filed with the Securities and Exchange Commission on August 14, 2025

Registration Statement File No. 333-60525 

Registration Statement File No. 333-51704 

Registration Statement File No. 333-53786 

Registration Statement File No. 333-143967

Registration Statement File No. 333-152359

Registration Statement File No. 333-182347

Registration Statement File No. 333-205267

Registration Statement File No. 333-225461

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-60525)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-51704)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-53786)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-143967)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-152359)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-182347)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-205267)

Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-225461)

UNDER

THE SECURITIES ACT OF 1933

 

 

Amedisys, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware    11-3131700

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA    70816
(Address of Principal Executive Offices)    (Zip Code)

Employee Stock Purchase Plan

Amedisys, Inc. 1998 Stock Option Plan

Amedisys, Inc. Directors’ Stock Option Plan

Amedisys, Inc. Employee Stock Purchase Plan

Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan

Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan

(Full title of the plan)

Scott G. Ginn

Chief Financial Officer

3854 American Way, Suite A

Baton Rouge, LA 70816

(Name and address of agent for service)

(225) 292-2031 or (800) 467-2662

(Telephone number, including area code, of agent for service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

DEREGISTRATION OF SECURITIES

Amedisys, Inc., a Delaware corporation (the “Company”), is filing these Post-Effective Amendments (these “Post-Effective Amendments”) to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) previously filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”), to deregister any and all shares of the Company’s common stock, par value $0.001 per share (the “Company Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof (note that the share numbers listed below do not take into account corporate actions, such as stock splits, taken in the interim):

 

   

Registration Statement on Form S-8 (Registration File No. 333-60525), which was filed with the Commission on August 3, 1998, pertaining to the registration of 1,000,000 shares of Company Common Stock under the Employee Stock Purchase Plan;

 

   

Registration Statement on Form S-8 (Registration File No. 333-51704), which was filed with the Commission on December 12, 2000, pertaining to the registration of 1,425,000 shares of Company Common Stock under the Company’s 1998 Stock Option Plan;

 

   

Registration Statement on Form S-8 (Registration File No. 333-53786), which was filed with the Commission on January 16, 2001, pertaining to the registration of 75,000 shares of Company Common Stock under the Company’s Directors’ Stock Option Plan;

 

   

Registration Statement on Form S-8 (Registration File No. 333-143967), which was filed with the Commission on June 22, 2007, pertaining to the registration of 2,500,000 shares of Company Common Stock under the Company’s 1998 Stock Option Plan and Employee Stock Purchase Plan;

 

   

Registration Statement on Form S-8 (Registration File No. 333-152359), which was filed with the Commission on July 16, 2008, pertaining to the registration of 1,862,459 shares of Company Common Stock under the Company’s 2008 Omnibus Incentive Compensation Plan;

 

   

Registration Statement on Form S-8 (Registration File No. 333-182347), which was filed with the Commission on June 26, 2012, pertaining to the registration of 4,100,000 shares of Company Common Stock under the Company’s 2008 Omnibus Incentive Compensation Plan and Employee Stock Purchase Plan;

 

   

Registration Statement on Form S-8 (Registration File No. 333-205267), which was filed with the Commission on June 26, 2015, pertaining to the registration of 1,500,000 shares of Company Common Stock under the Company’s 2008 Omnibus Incentive Compensation Plan; and

 

   

Registration Statement on Form S-8 (Registration File No. 333-225461), which was filed with the Commission on June 6, 2018, pertaining to the registration of 2,500,000 shares of Company Common Stock under the Company’s 2018 Omnibus Incentive Compensation Plan.

On June 26, 2023, the Company entered into that certain Agreement and Plan of Merger with UnitedHealth Group Incorporated, a Delaware corporation (“UnitedHealth Group”) and Aurora Holdings Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of UnitedHealth Group (“Merger Sub”), which provides for the merger of Merger Sub with and into the Company, with the Company surviving as a wholly owned subsidiary of UnitedHealth Group (the “Merger”). The Merger became effective on August 14, 2025, pursuant to a Certificate of Merger filed with the Secretary of State of the State of Delaware.

In connection with the Merger, the Company has terminated any and all of the offerings of the Company’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold or otherwise unissued at the termination of the offerings, the Company hereby amends the Registration Statements and removes from registration any and all of the securities of the Company registered under the Registration Statements that remain unsold or otherwise unissued as of the date of these Post-Effective Amendments, and hereby terminates the effectiveness of each of the Registration Statements.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Baton Rouge, State of Louisiana, on the 14th day of August, 2025.

 

AMEDISYS, INC.,
By:   /s/ Richard Ashworth
Name:   Richard Ashworth
Title:   President and Chief Executive Officer

 

Note:

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

FAQ

What did Amedisys (AMED) file in this S-8 POS notice?

The company filed a notice to deregister shares of common stock that remain registered but unsold or unissued under eight prior S-8 registration statements.

Which employee plans are affected by the deregistration?

The notice references the Employee Stock Purchase Plan, Directors' Stock Option Plan, the 1998 Stock Option Plan, the 2008 Omnibus Incentive Compensation Plan, and the 2018 Omnibus Incentive Compensation Plan as applicable to the listed registrations.

How many shares were originally registered under the listed S-8 filings?

The filing lists original registration amounts including 1,000,000; 1,425,000; 75,000; 2,500,000; 1,862,459; 4,100,000; 1,500,000; and 2,500,000 shares for the respective filings.

Does this filing change Amedisys’ outstanding share count?

No. The notice deregisters registered but unsold or unissued shares; it does not state any issuances or cancellations and notes share counts may differ after interim corporate actions.

Who signed the deregistration notice for Amedisys?

The filing is signed by Richard Ashworth, identified as President and Chief Executive Officer.
Amedisys Inc

NASDAQ:AMED

AMED Rankings

AMED Latest News

AMED Latest SEC Filings

AMED Stock Data

3.32B
32.24M
1.95%
96.37%
9.73%
Medical Care Facilities
Services-home Health Care Services
Link
United States
BATON ROUGE